/* */ PELVIPHARM - Testosterone-induced rat model of BPH
Receive our news

 

Testosterone-induced rat model of BPH

Model advantages

The main advantage of the testosterone-induced rat model of BPH is that it presents an enlargement of the prostate sharing common characteristics with human BPH and thus allowing studies on the causative mechanism of BPH symptoms by specifically targeting the prostatic growth and its final consequences.

Pathophysiological features

Prostate features :
The testosterone-induced rat model of BPH exhibits several common characteristics with the human pathology :

  • Prostatic enlargement
  • Both stromal and epithelial compartments proliferation (figure 1).
Figure 1: Representative microphotographs of rat prostatic lateral lobes stained with hematoxylin-eosin (HE) observed at x100 magnification in sesame oil (left panel) and testosterone (right panel)-treated rats (3 weeks, 3 mg/kg/d) (Pelvipharm, internal data).
Figure 1: Representative microphotographs of rat prostatic lateral lobes stained with hematoxylin-eosin (HE) observed at x100 magnification in sesame oil (left panel) and testosterone (right panel)-treated rats (3 weeks, 3 mg/kg/d) (Pelvipharm, internal data).

Bladder features

  • Abnormal bladder function similar to that of patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: increase in bladder capacity, in maximal amplitude of bladder contractions and in residual volume, occurrence of non voiding contractions
  • Bladder hypertrophy



Figure 2: Representative cystometrograms in conscious testosterone or vehicle-treated rats. (Pelvipharm, internal data).
Figure 2: Representative cystometrograms in conscious testosterone or vehicle-treated rats. (Pelvipharm, internal data).

Urethra features

  • Increase in urethral pressure
  • Increase in urethral phenylephrine-responsiveness in vivo

Summarized methodology

The hormonal-induced prostate hypertrophy in rats is induced by the daily subcutaneous delivery of testosterone (figure 3).

Figure 3: Evaluation of prostate enlargement induced by daily s.c. testosterone injections (3mg/kg during 3 weeks) (Pelvipharm, internal data)
Figure 3: Evaluation of prostate enlargement induced by daily s.c. testosterone injections (3mg/kg during 3 weeks) (Pelvipharm, internal data)
Related Pelvipharm bibliography
Julia-Guilloteau, V. et al.
Eur Urol (2006) : 5(2):119 (EAU, 2006)
SITEMAP
TEL +331 704 293 39
FAX + 331 704 295 10
LEGAL